Chromium Induced Developments of Diseases and their Inhibitions by Cargos

Ardhendu Kumar Mandal *

Central Instrumentation Division CSIR-Indian Institute of Chemical Biology, India.

*Author to whom correspondence should be addressed.


The exposure of hexavalent chromium (Cr-VI) mainly through the inhalation, skin contact or oral administration by the environmental chromium industrial processes causes the major toxicity-induced health hazardous mortality throughout the world. Though reduced chromium (Cr-III), as an essential micronutrient, is utilized to maintain the normal blood glucose, lipid and protein profiles through the metabolism in the body to activate the action of the hormones such as insulin, the high concentration exposures of Cr-VI and Cr-III cause oxidative stress-induced DNA oxidation and adducts, DNA strand breaks and mutations, DNA-protein cross-links, membrane-lipid peroxidation and reduced/altered antioxidant/immune response activities, leading to cellular damage-related various diseases and the development of malignant cancer.

Applications of different cargos may inhibit Cr-VI or its intermediates-induced cytotoxicity, immunotoxicity, or genotoxicity through chromium-chelating and scavenging free radical reactive species, restoring antioxidant and immune response activities or arresting disease-oriented signal transductions or other pathways at cellular and molecular levels. This review mainly demonstrates  the development  of various  diseases by chromium exposure and their inhibitions by cargos.

Keywords: Hexavalent chromium, oxidative stress, diseases, cargos, inhibition

How to Cite

Mandal, A. K. (2022). Chromium Induced Developments of Diseases and their Inhibitions by Cargos. Asian Journal of Biochemistry, Genetics and Molecular Biology, 12(4), 108–119.


Download data is not yet available.


Urbano AM, Ferreira LMR, Alpoim MC. Molecular and cellular mechanisms of hexavalent chromium-induced lung cancer: An updated perspective. Curr Drug Metabol. 2012;13:284-305.

Ghosh P, Dey T, Chattopadhyay A, Bandyopadhyay D. An insight into the ameliorative effects of melatonin against chromium induced oxidative stress and DNA damage: A review. Melatonin Res. 2021;4(3):377-407.

Zhitkovich A. Chromium in drinking water: Sources, metabolism and cancer risks. Chem Res Toxicol. 2011;24:1617- 1629.

Nickens KP, Patierno SR, Ceryak S. Chromium genotoxicity: A double-edged sword. Chem Biol Interact. 2010;188(2): 276-288.

Ray RR. Adverse hematological effects of hexavalnt chromium: An overview. Interdiscip Toxicol. 2016;9(2): 55-65.

Zablon HA, VonHandorf A, Puga A. Chromium exposure disrupts chromatin architecture upsetting the mechanisms that regulate transcription. Experiment Biol Med. 2019;244:752-757.

Wang BJ, Chiu HW, Lee YL, Li CY, Wang YJ, Lee YH. Pterostilbene attenuates hexavalent chromium-induced allergic contact dermatitis by preventing cell apoptosis and inhibiting IL-1β-related NLRP3 inflammasome activation. J Clin Med. 2018;7:489.

Xiao F, Chen D, Luo L, Zhong X, Xie Y, Zou L, Zeng M, Guan L, Zhong C. Time-order effects of vitamin C on hexavalent chromium-induced mitochondrial damage and DNA- protein crosslinks in cultured rat peripheral blood lymphocytes. Mol Med Reports. 2013;8:53-60.

Iztleuov Y, Abilov T, Zhanabayeva G, Ismailova I, Iztleuov M. Protective effect of sodium tetraborate on chromium-induced brain damage in rats. Biomed Pharmacol J. 2018;11(1):227-236.

Garcia-Nino WR, Pedraza-Chaverri J. Protective effect of curcumin against heavy metals-induced liver damage. Food Chem Toxicol. 2014;69:182-201.

Wang Y, Su H, Gu Y, Song X, Zhao J. Carcinogenecity of chromium and chemoprevention: A brief update. OncoTargets Therapy. 2017;10:4065-4079.

Mandal AK. Silver nanoparticles as drug delivery system in combating infections and cancer. In Book: Farzaneh Mohamadpour, Editor. Challenges and advances in pharmaceutical research Vol. 4. India-United Kingdom: Book Publisher International. 2022;Cp 14: pp 165-179.

Mandal AK. Mitochondrial targeting of potent nanoparticulated drugs in combating diseases. J Biomater Appl. 2022;37(4):614-633.

Pratheeshkumar P, Son YOK, Divya AP, Wang L, Turcios L, Roy RV, Hitron JA, Kim D, Dai J, Asha P, Zhang Z, Shi X. Quercetin inhibits Cr(VI)-induced malignant cell transformation by targeting miR-21-PDCD4 signaling pathway. Oncotarget. 2017;8(32):52118-52131.

Pratheeshkumar P, Son YOK, Divya SP, Roy RV, Hitron JA, Wang L, Kim D, Dai J, Asha P, Zhang Z, Wang Y, Shi X. Luteolin inhibits Cr(VI)-induced malignant cell transformation of human lung epithelial cells by targeting ROS mediated multiple cell signaling pathways. Toxicol Appl Pharmacol. 2014;281(2):230-241.

Shrivastava R, Upreti RK, Seth PK, Chaturvedi UC. Effects of chromium on the immune system. FEMS Immunol Medic Microbiol. 2002;34:1-7.

Chen L, Ovesen JL, Puga A, Xia Y. Distinct contributions of JNK and p38 to chromium cytotoxicity and inhibition of murine embryonic stem cell differentiation. Environ Health Perspect. 2009;117:1124-1130.

Wang X, Mandal AK, Saito H, Pulliam JF, Lee EY, Ke ZJ, Lu J, Ding SZ, Li L, Shelton BJ, Tucker T, Evers BM, Zhang Z, Shi X. Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/β-catenin signaling pathway. Toxicol Appl Pharmacol. 2012;262(1):11-21.

Luczak MW, Krawic C, Zhitkovich A. p53 activation by Cr(VI): A transcriptionally limited response induced by ATR kinase in S-phase. Toxicol Sci. 2019;172(1):11- 22.

Wise JJP, Young JL, Cai J, Cai L. Current understanding of hexavalent chromium [Cr(VI)] neurotoxicity and new perspectives. Environ Int. 2022;158: 106877.

Xu Y, Wang L, Zhu J, Jiang P, Zhang Z, Li L, Wu Q. Chromium induced neurotoxicity by altering metabolism in Zebrafish larvae. Ecotoxicol Environ Safety. 2021;228: 112983.

Lee JW, Kim JH, Lee DC, Lim HJ, Kang JC. Toxic effects on oxidative stress, neurotoxicity, stress and immune responses in Juvenile Olive Flounder, Paralichthys olivaceus, exposed to waterborne hexavalent chromium. Biol. 2022;11:766.

Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1-40.

Mandal AK. Melatonin as potent therapeutic drug in vesicular delivery application in combating diseases. Glob J Nanomed. 2021;5(4):555669.

Ghosh A, Sarkar S, Mandal AK, Das N. Neuroprotective role of nanoencapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One. 2013; 8(4):e57735.

Cantero G, Campanella C, Mateos S, Cortes F. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagenesis. 2006;21(5):321-325.

Sudan S, Rupasinghe HPV. Quercetin-3-0-gucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2014;34(4):1691-1699.

Mandal AK, Ghosh A, Das N. Vesicular drug targeting in combating cerebral oxidative injury. Ind J Appl Res. 2018;8(1):287-292.

Sana S, Ghosh S, Das N, Sarkar S, Mandal AK. Vesicular melatonin efficaciently downregulates sodium fluoride-induced rat hepato and broncho TNF-α, TGF-β expressions and associated oxidative injury: A comparative study of liposomal and nanocapsulated forms. Int J Nanomed. 2017;12:4059-4071.

Mandal AK, Ghosh D, Sarkar S, Ghosh A, Swarnakar S, Das N. Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine induced carcinoma. Nanomed (Lond). 2014; 9(15):2323-2337.

Ghosh D, Thakur Choudhury S, Ghosh S, Mandal AK, Sarkar S, Ghosh A, Das Saha K, Das N. Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem boil Interact. 2012;195(3): 206-214.

Mandal AK, Joardar A. Manganese nanomaterials as delivery system in combating diseases. Int J Curr Res. 2021;13(10):19306-19315.

Mandal AK. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int J Polym Mater Polym Biomater. 2021;70(4):287-297.